Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Dziusmikeyeva, A. Zalutskaya, A. Skrahin, A. Prasmyzki, V. Solodovnikova, A. Skrahina (Minsk, Belarus). Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis. Eur Respir J 2011; 38: Suppl. 55, 4407

Member's Comments

No comment yet.

Related content which might interest you: Adverse events in the treatment of multidrug-resistant tuberculosis Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 650s Year: 2005 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 Adverse reactions during treatment of multidrug-resistant and extensively drug-resistant tuberculosis Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Statin with standard antituberculosis regimen and mortality in hospitalized pulmonary tuberculosis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001 Monitoring of drug resistance of TB mycobacteria in new pulmonary TB patients Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Relapse and failure pulmonary tuberculosis patients have the chance of cure with major antituberculosis drugs Source: Eur Respir J 2007; 30: Suppl. 51, 657s Year: 2007 Adverse effects of chemotherapy in patients with multidrug-resistant tuberculosis with alcohol abuse and without one Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Resistance of sputum nonspecific microflora in MDR TB patients treated with second-line anti-TB drugs Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002